FDA approves drug to treat dangerously low blood pressure
- Details
- Written by IVN
- Category: Health News
Washington, DC - The U.S. Food and Drug Administration today approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive shock.
Abuse and adversity in childhood linked to more cardiovascular risk in adulthood
- Details
- Written by American Heart Association
- Category: Health News
Dallas, Texas - Children and teens who are abused, witness violence, are bullied or face other adversities are more likely to develop cardiovascular diseases in adulthood, according to a new scientific statement by the American Heart Association published in the Association’s journal Circulation.
Researchers explore complex genetic network behind sleep duration
- Details
- Written by IVN
- Category: Health News
Washington, DC - Scientists have identified differences in a group of genes they say might help explain why some people need a lot more sleep - and others less - than most. The study, conducted using fruit fly populations bred to model natural variations in human sleep patterns, provides new clues to how genes for sleep duration are linked to a wide variety of biological processes.
FDA to support more efficient development of targeted therapies
- Details
- Written by FDA Commissioner Scott Gottlieb, M.D.
- Category: Health News
Washington, DC - In recent years, the medical community has experienced a shift in the way health care is practiced. Rather than focusing solely on how to treat an overall disease type, medical innovators are now exploring how to tailor treatments that target unique characteristics of an individual’s disease, such as the genetic profile of a person's tumor. Innovation in this modern, targeted approach to medicine has already led to new more targeted medicines and, in some cases, therapies that are tailored to individual patients.
Omalizumab improves efficacy of oral immunotherapy for multiple food allergies
- Details
- Written by NIH
- Category: Health News
Washington, DC - Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.
FDA launches new tool for sharing information that allows doctors to better manage antibiotic use
- Details
- Written by IVN
- Category: Health News
Washington, DC - Today the U.S. Food and Drug Administration is announcing a new approach to get critical updates regarding antibiotics and antifungal drugs to health care professionals as part of an overall effort to combat antimicrobial resistance. The agency created a website that will provide direct and timely access to information about when bacterial or fungal infections are likely to respond to a specific drug. This approach is intended to aid health care professionals in making more informed prescribing decisions that will both benefit their patients and prevent the spread of resistant bacteria.
Page 2944 of 3785